Stevanato Group
Develops pharmaceutical containment, delivery, diagnostic, and manufacturing solutions for drug-development and production workflows.
Something off on this page? Send us feedback.
Profile
Supplies pharmaceutical-grade containment and delivery products, diagnostic solutions, engineering equipment, and analytical services. Its integrated platform serves pharmaceutical and biotechnology customers across development, clinical, and commercial stages, pairing technical manufacturing with a global production footprint.
Pharmaceutical-grade containment and delivery products sit alongside diagnostic solutions, engineering equipment, and analytical services. The platform spans containment, delivery, diagnostics, and manufacturing services. It supports pharmaceutical and biotechnology customers from development through clinical and commercial stages.
Manufacturing expanded from Italy to sites in Mexico, China, Brazil, and the United States; the Fishers, Indiana facility produces EZ-fill syringes and vials while supporting North American engineering after-sales work. Acquisitions added inspection-machine, diagnostic-consumable, drug-delivery, and medical-component capabilities.
The business depends on integrated product, process, and service delivery for regulated pharmaceutical and biotechnology customers.
Company facts
Categories
Key statistics
Year to date +2.4% · Average volume (30d) 450.7K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Mar 5, 2026 | Keybanc | Reiterate | Overweight | $32 | |
| Feb 10, 2026 | Jefferies | Target | $17.50 | ||
| Dec 1, 2025 | Morgan Stanley | Target | $22 | $24 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026Q2 FY26 | $0.14 | $0.16 | +10.5% | $340.6M | $344.9M | +1.3% | −4.57% |
| May 7, 2026Q1 FY26 | $0.12 | $0.13 | +8.3% | $310.5M | $316.1M | +1.8% | +1.11% |
| Mar 4, 2026Q4 FY25 | $0.20 | $0.21 | +5.0% | $391.3M | $407.0M | +4.0% | −9.09% |
| Nov 6, 2025Q3 FY25 | $0.14 | $0.16 | +14.3% | $385.5M | $355.1M | −7.9% | −1.27% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $297.3M | $324.5M | $351.3M | $397.7M | $317.0M | $349.9M | |
| Gross profit | $81.0M | $91.1M | $102.5M | $122.7M | $87.1M | $100.6M | |
| Operating income | $40.1M | $47.9M | $61.1M | $76.4M | $44.9M | $45.3M | |
| Net income | $30.7M | $34.4M | $41.8M | $54.6M | $32.5M | $26.6M | |
| Diluted EPS | $0.12 | $0.13 | $0.15 | $0.20 | $0.12 | $0.09 | |
| Gross margin | 27.2% | 28.1% | 29.2% | 30.9% | 27.5% | 28.7% | |
| Operating margin | 13.5% | 14.8% | 17.4% | 19.2% | 14.2% | 12.9% |
Fiscal years (4-quarter sums)FY21 $977.8M · FY22 $1.14B · FY23 $1.26B · FY24 $1.28B · FY25 $1.37B
Revenue by geography · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $96.8M · Total debt $513.3M · Total assets $3.03B · Shareholders' equity $1.80B
Dividends
Raised for 3 straight years — most recently to $0.0622 from $0.0618 in Jun 2026. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jun 11, 2026 | Jun 11 | Jul 29 | $0.0622 | raised from $0.0618 |
| Jun 5, 2025 | Jun 5 | Jul 17 | $0.0618 | raised from $0.058 |
| Jun 4, 2024 | Jun 4 | Jul 15 | $0.058 | raised from $0.0578 |
| Jun 7, 2023 | Jun 6 | Jul 17 | $0.0578 | raised from $0.051 |
| Jun 13, 2022 | Jun 14 | Jul 13 | $0.051 |
Ownership
Shares outstanding 273.01M · Float 273.01M · 100.0% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Conestoga Capital Advisors, LLC | 7.01M | 2.57% | 13F | Jul 24, 2026 |
| Neuberger Berman Group LLC | 5.62M | 2.06% | 13F | Aug 13, 2026 |
| Timessquare Capital Management, LLC | 3.47M | 1.27% | 13F | Aug 7, 2026 |
| T. Rowe Price Investment Management, Inc. | 3.22M | 6.50% | 13G | May 15, 2026 |
| Van Berkom & Associates Inc. | 2.97M | 6.00% | 13G | Aug 4, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 7, 2026 | Elisabetta Magistretti | director | −2,045 | $20.09 |
| Aug 7, 2026 | Lago Marco Dal | officer: Chief Financial Officer | −4,209 | $20.09 |
| Aug 7, 2026 | Luciano Santel | director | −2,023 | $20.09 |
| Jun 15, 2026 | William J. Federici | director | −1,493 | $17.09 |
| Jun 15, 2026 | Karen Flynn | director | −1,493 | $17.09 |
Peers
- West Pharmaceutical Services
Injectable containment, delivery-device, and CDMO rival.
- BD
Prefillable syringe and self-injection systems rival.
- ATS (ADR)
Life-sciences automation and pharmaceutical-packaging rival.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Stevanato Group | $21.15 | +0.33% | $5.74B | 37.8 | 26.6 | 4.1 | +4.6% |
| West Pharmaceutical Services | $349.58 | +3.61% | $23.75B | 43.2 | 36.5 | 7.1 | +13.9% |
| BD | $189.00 | −0.27% | $52.22B | 57.1 | 14.3 | 2.5 | −9.6% |
| ATS (ADR) | $19.21 | −0.03% | $1.88B | 56.0 | 21.7 | 0.9 | −9.7% |
| Median | 56.0 | 21.7 | 2.5 | −9.6% |